Glimepiride 3mg

| Override(s) | Approval Duration |
|---------------------|----------------------------------|
| Prior Authorization | 1 year |
| Quantity Limit | |
| | |
| Medications | Quantity Limit |
| | |
| Glimepiride 3mg | May be subject to quantity limit |

APPROVAL CRITERIA

Individuals requesting glimepiride 3mg must also meet the following criteria:

- I. Individual has had a trial of generic glimepiride. Medication samples/coupons/discount cards are excluded from consideration as a trial; **AND**
- II. Documentation is provided that individual is unable to achieve glycemic control with the available generic glimepiride strengths (1 mg, 2 mg, 4 mg).

Key References:

- 1. DailyMed. Package inserts. U.S. National Library of Medicine, National Institutes of Health website. http://dailymed.nlm.nih.gov/dailymed/about.cfm. Accessed: April 3, 2024.
- DrugPoints® System [electronic version]. Truven Health Analytics, Greenwood Village, CO. Updated periodically.
- 3. Lexi-Comp ONLINE[™] with AHFS[™], Hudson, Ohio: Lexi-Comp, Inc. Updated periodically.
- Samson SL, Vellanki P, Blonde L, et. al. American Association of Clinical Endocrinologists (AACE) Consensus Statement: Comprehensive Type 2 Diabetes Management Algorithm – 2023 Update. *Endocrine Practice*. 2023;29:305-340.
- 5. US Food and Drug Administration. FDA Drug Safety Communication: FDA revises warnings regarding use of the diabetes medicine metformin in certain patients with reduced kidney function. Last updated: November 14, 2017. Available at https://www.fda.gov/Drugs/DrugSafety/ucm493244.htm. Accessed: March 31, 2024.

Federal and state laws or requirements, contract language, and Plan utilization management programs or polices may take precedence over the application of this clinical criteria.

No part of this publication may be reproduced, stored in a retrieval system or transmitted, in any form or by any means, electronic, mechanical, photocopying, or otherwise, without permission from the health plan.